Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are researching regenerative medicine, you will quickly notice the word "autologous." It appears in clinic descriptions, research papers and consent documents, yet it is rarely explained in plain language. This article explains what the term means, how treatment with your own cells differs from treatment with donor cells, and what questions are worth raising before a consultation at Grand Green Osaka Umekita Clinic or any other clinic.
The short answer: autologous means your own cells
"Autologous" simply means that the cells come from the same person who receives them. In adipose-derived stem cell therapy, a very small amount of your own fat tissue is collected, the mesenchymal stem cells it contains are cultured and expanded at a specialized facility, and the cells are then returned to you by IV infusion. The opposite term is "allogeneic," which describes cells taken from a different person, such as a donor.
This distinction matters because the immune system is built to recognize cells that do not belong to the body. Using your own cells is generally considered to lower the risk of rejection or allergic reaction compared with donor cells or artificial materials. However, lower risk does not mean no risk, and an individual doctor's assessment is always required.
How autologous and donor-derived cells differ
Mesenchymal stem cells are somatic stem cells found in fat tissue, bone marrow and other tissues. They are able to differentiate into fat, bone and cartilage cells, and they have been reported to secrete anti-inflammatory substances and growth factors that may support the repair of damaged tissue. Researchers have studied both autologous and allogeneic sources of these cells.
Several practical differences are often discussed in the scientific literature:
- Immune compatibility: your own cells are recognized as "self," whereas donor cells may provoke an immune response in some situations.
- Preparation time: autologous cells must be collected, cultured and expanded for each individual, so there is a waiting period before infusion.
- Variability: the quality and number of cells obtained can differ from person to person, and may be influenced by age and general health.
- Traceability: with own-cell treatment, the cells belong to one patient from collection to infusion, which can simplify record keeping.
Neither approach is simply better in every case. The research is still developing, and findings from one study should not be generalized to every patient or condition.
Why fat tissue is used as the source
Mesenchymal stem cells can also be harvested from bone marrow, but bone marrow collection places a considerable burden on the body. Fat tissue is considered to contain more mesenchymal stem cells than bone marrow, and it can be collected through a small incision under local anesthesia. Only a few rice-grain-sized pieces of fat are needed. Because collection and infusion are both performed on an outpatient basis, treatment does not require hospitalization.
That said, any procedure involving a small incision carries its own considerations, such as bleeding, infection or discomfort at the collection site. These are the kinds of points a doctor should explain to you in person before you decide anything.
What "lower risk" does and does not mean
It is easy to hear "your own cells" and assume the treatment is risk-free. That would be a misunderstanding. Even with autologous cells, risks can arise from the collection procedure, the culture process, the infusion itself, or a person's underlying health conditions. Reported effects in research also vary, and results seen in a study population cannot be promised to any individual.
Adipose-derived stem cell therapy is not a replacement for standard medical care. If you are currently being treated for a condition, your regular doctor remains an important part of your care, and you should tell the clinic about all of your diagnoses and medications.
How Japanese law and self-pay care fit in
In Japan, regenerative medicine that uses cultured cells is provided under the Act on the Safety of Regenerative Medicine, which requires a provision plan reviewed by a certified committee and submitted to the authorities. This framework is intended to support safety management and transparency, though it does not by itself guarantee any outcome.
Adipose-derived stem cell therapy is offered as self-pay medical care, meaning it is not covered by public health insurance. Costs, the number of treatments, risks, side effects and whether the therapy is suitable for you must all be confirmed with a doctor during a consultation.
Questions to prepare before a consultation in Osaka
Grand Green Osaka Umekita Clinic is located in Umeda, Osaka, and offers an information page for international patients. If you are considering a consultation, it can help to prepare a short list of questions in advance, such as:
- Are the cells used in this treatment strictly my own, and how are they identified and tracked?
- What are the possible risks and side effects of collection, culture and infusion?
- How is the treatment provided under Japan's regenerative medicine law?
- What are the total costs, and which items are not included?
- How should my current medications and medical history be taken into account?
- What follow-up is available after I return home?
Bringing medical records in English, if you have them, can make the discussion more efficient. The doctor will then decide, based on your examination, whether this treatment is appropriate to discuss further.
Summary
Autologous means that the cells used in treatment come from your own body. In adipose-derived stem cell therapy, this typically involves collecting a small amount of fat, culturing the mesenchymal stem cells and returning them by IV infusion. Using your own cells is generally associated with a lower risk of rejection or allergic reaction than donor cells, but it does not remove all risks or guarantee any result. Because the therapy is self-pay and provided under Japan's regenerative medicine framework, the most useful step is to bring clear questions to a consultation and let a doctor assess your individual situation.
Autologous
- Cells from your own fat
- Cultured for each patient
- Preparation time needed
Allogeneic
- Cells from another person
- Immune response may occur
- Different sourcing process
This figure is a conceptual diagram that summarizes the content of the article
References
- PMC: The Importance of HLA Assessment in "Off-the-Shelf" Allogeneic Mesenchymal Stem Cells Based-Therapies. (2019)
- PMC: Clinical implication of allogenic implantation of adipogenic differentiated adipose-derived stem cells. (2014)
- PMC: Allogeneic ADSCs Induce the Production of Alloreactive Memory-CD8 T Cells through HLA-ABC Antigens. (2020)
- PMC: Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? (2017)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.